학술논문
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis
Document Type
Article
Author
Source
In: The Lancet Oncology . (The Lancet Oncology, November 2021, 22(11):1573-1581)
Subject
Language
English
ISSN
14745488
14702045
14702045